Physician profile
Michael G Brummer
NPI 1427033521
$477.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $183 · 2022: $13.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $121.40 | 2020 | |
| Amgen INC. | $101.86 | 2019-2020 | |
| Ge Healthcare | $35.67 | 2019 | |
| Novo Nordisk INC | $35.45 | 2019-2020 | |
| Celgene Corporation | $32.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $32.81 | 2019 | |
| Pfizer INC. | $25.18 | 2019 | |
| Acadia Pharmaceuticals INC | $25.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.19 | 2019 | |
| Abbvie INC. | $13.29 | 2022 | |
| Sanofi Pasteur INC. | $12.86 | 2019 | |
| Medtronic Minimed, INC. | $11.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.